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Abstract
Switching to a glycolytic metabolism is a rapid adaptation of tumor cells to hypoxia. Although this metabolic conversion
may primarily represent a rescue pathway to meet the bioenergetic and biosynthetic demands of proliferating tumor cells, it
also creates a gradient of lactate that mirrors the gradient of oxygen in tumors. More than a metabolic waste, the lactate
anion is known to participate to cancer aggressiveness, in part through activation of the hypoxia-inducible factor-1 (HIF-1)
pathway in tumor cells. Whether lactate may also directly favor HIF-1 activation in endothelial cells (ECs) thereby offering a
new druggable option to block angiogenesis is however an unanswered question. In this study, we therefore focused on
the role in ECs of monocarboxylate transporter 1 (MCT1) that we previously identified to be the main facilitator of lactate
uptake in cancer cells. We found that blockade of lactate influx into ECs led to inhibition of HIF-1-dependent angiogenesis.
Our demonstration is based on the unprecedented characterization of lactate-induced HIF-1 activation in normoxic ECs and
the consecutive increase in vascular endothelial growth factor receptor 2 (VEGFR2) and basic fibroblast growth factor (bFGF)
expression. Furthermore, using a variety of functional assays including endothelial cell migration and tubulogenesis
together with in vivo imaging of tumor angiogenesis through intravital microscopy and immunohistochemistry, we
documented that MCT1 blockers could act as bona fide HIF-1 inhibitors leading to anti-angiogenic effects. Together with the
previous demonstration of MCT1 being a key regulator of lactate exchange between tumor cells, the current study identifies
MCT1 inhibition as a therapeutic modality combining antimetabolic and anti-angiogenic activities.
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Introduction
Solid tumors most often exhaust their oxygen supply creating
tumor hypoxia [1]. Hypoxia initially triggers a key metabolic
adaptation, the glycolytic switch, during which glycolysis is
uncoupled from the TCA cycle and becomes the primary source
of ATP production. This process is extremely fast as it initially
proceeds through inhibition of the Pasteur effect, a negative feedback
exerted by energy metabolites on the glycolytic flux [2]. Glycolysis is
rather inefficient at producing energy, yielding only 2 ATP
molecules per molecule of glucose whereas full glucose oxidation
provides up to 38 ATP. Further adaptations are thus needed to
support cell survival and proliferation under sustained (or repeated
episodes of) hypoxia. Two main biological paths have evolved. On
the one hand, tumor cells exhibit an accelerated glycolytic flux to
meet their high bioenergetic and biosynthetic demands indepen-
dently of oxygen but at the cost of high glucose consumption and
lactate release [3–5]. On the other hand, the angiogenic switch,
corresponding to the initiation of vascular extension, aims at
increasing oxygen and nutrient supply to hypoxic tumor sites [6].
These two adaptations require de novo protein synthesis and share the
transcription factor HIF-1 as a master regulator.
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HIF-1 is an ab-heterodimer: the HIF-1b subunit is constitutively
nuclear whereas HIF-1a is inducible by hypoxia [7]. Regulation of
HIF-1a protein level involves its posttranslational hydroxylation at
proline residues 402 and 564 (human sequence) by prolylhydrox-
ylases (PHDs), predominantly PHD2 [8]. PHDs are Fe(II)- and 2-
oxoglutarate-dependent dioxygenases that have an absolute re-
quirement for molecular oxygen [9]. In oxygenated cells, proline
hydroxylations target HIF-1a to the von Hippel-Lindau protein
complex for poly-ubiquitylation followed by proteasome-dependent
degradation [10]. Under hypoxia, HIF PHDs are inactivated, HIF-
1a escapes proteolytic degradation, migrates to the cell nucleus, and
binds to HIF-1b and co-factors to initiate the transcription of target
genes. These target genes include glucose transporters, most
glycolytic enzymes, the lactate transporter monocarboxylate
transporter 4 (MCT4) and key pro-angiogenic effectors such as
vascular endothelial growth factor (VEGF) [11,12]. Because HIF-1
promotes both glycolytic energy production and angiogenesis, it is
not surprising that increased levels of HIF-1a are associated with
poor cancer prognosis [13,14].
Several pieces of evidence suggest that the glycolytic switch
triggers angiogenesis [15]. The most direct coupling is probably
exerted by lactate, the end-product of glycolysis. Lactate has been
known for many years to promote angiogenesis in wounds. It
promotes collagen deposition [16,17] and enhances VEGF
production and activity in fibroblasts [18] and macrophages
[19]. The underlying mechanism has been proposed to involve
lactate oxidation to pyruvate, together with a decrease in NAD+
and a subsequent decrease in protein poly-ADP-ribosylation [17–
20]. In glioma tumor cells, lactate was further shown to trigger
HIF-1 activation in a hypoxia-independent manner through
inhibition of HIF-1a proline hydroxylations [21,22], resulting in
increased VEGF production by tumor cells.
A direct impact of lactate on HIF-1a expression in endothelial
cells has however not been documented. We recently reported that
lactate could stimulate nuclear factor-kappa B (NF-kB) activation
and interleukin-8 (IL-8) production in ECs [23], proving that these
cells could act as a lactate signaling platform continuously fueled
by the elevated lactate concentration (1–40 mM) present in the
tumor microenvironment [24]. In this study, we report that lactate
stimulates HIF-1 activity in ECs, which directly accounts for
angiogenesis independently of any additional pro-angiogenic
stimulus. We further identify the lactate transporter monocarbox-
ylate transporter 1 (MCT1) as the main regulator of HIF-1
activation by lactate in ECs, and provide unprecedented evidence
that HIF-1 inhibition and the associated blockade of angiogenesis
may be obtained through MCT1 inhibition.
Results
ECs take up exogenous lactate
Confluent ECs were exposed to 10 mM sodium L-lactate, a
concentration that corresponds to the level of lactate most
commonly detected in human tumors [25]. 13C-lactate (methyl-
labeled) was used in nuclear magnetic resonance (NMR)
experiments. 13C NMR spectra of cell lysate collected 6-h after
treatment showed a peak at 19 ppm corresponding to intracellular
13C-lactate (Figure 1A). In the same conditions, 1H NMR spectra
showed doublets arising from intracellular 13C-lactate at 1.56 and
1.30 ppm, thus confirming that ECs import exogenous lactate
(Figure 1B). The uptake rate was quantified in an enzymatic assay
specific for L-Lactate. Kinetic analyses revealed a time-dependent
increase in intracellular lactate after exposure to 10 mM
extracellular lactate (Figure 1C).
Exogenous lactate activates HIF-1 in normoxic ECs
Lactate is known to fuel oxidative phosphorylation in tumor
cells and favors cell proliferation even in the absence of an
exogenous source of serum or growth factors [26]. In similar
serum-free conditions, however, lactate cannot rescue glucose-
deprived ECs as documented by an accelerated increase in cell
death (Figure S1A). In the presence of glucose, it did not modulate
the oxygen consumption rate (Figure S1B). In the following
experiments, we therefore examined the signaling effects of lactate
added to the growth medium of ECs and we focused on HIF-1,
based on previous reports in tumor cells [21,22]. Using a dual
luciferase reporter assay in normoxic ECs, we found increased
HIF-1 activity after a 24-h treatment with 10 mM lactate
(Figure 2A). Consistent with HIF-1 activation, we evidenced the
nuclear translocation of HIF-1a (Figure S2). VEGF and basic
fibroblast growth factor (bFGF) are major pro-angiogenic agents
[27]. VEGF-A is encoded by a HIF-1 target gene [28] while bFGF
expression is indirectly induced by HIF-1 [29]. To further
investigate HIF-1 activation by lactate, we probed changes in
VEGF-A and bFGF release in the supernatant of confluent human
umbilical vein endothelial cells (HUVECs) using ELISA. VEGF-A
levels were unchanged (Figure 2B) but a 3-fold increase in bFGF
secretion was detected after a 24-h incubation with 10 mM lactate
(Figure 2C). The same treatment significantly increased the
protein expression of VEGF receptor-2 (VEGFR2/flk-1)
(Figure 2D), the major transducer of VEGF-mediated angiogenesis
in ECs [27]. Increased membrane VEGFR2 expression was
confirmed using specific immunostaining in HUVECs (Figure
S3A). PCR arrays further revealed that lactate upregulated the
transcription of 31 genes in HUVECs by at least,2-fold, of which
10 are known to be direct HIF-1 target genes (Table S1).
HIF-1 activity primarily depends on the stable expression of its
a subunit [7]. In normoxic HUVECs, lactate (10 mM) induced a
significant increase in HIF-1a protein expression 24-h after
treatment (Figure 3A). Similar induction was observed in bovine
aortic ECs (BAECs) (Figure 3B). Induction of HIF-1a by lactate
was concentration-dependent with a plateau corresponding to a 3-
fold increase in HIF-1a protein expression reached after a 24-h
exposure to lactate concentrations $10 mM (Figure 3C). It was
also time-dependent with a 5-fold induction peak at 3-h followed
by a slow decrease (Figure 3D).
The canonical regulation of HIF-1 activity involves the
posttranslational hydroxylation of HIF-1a on 2 proline residues,
a reaction catalyzed by HIF PHDs that promotes HIF-1a
degradation [8]. Our observations that lactate did not significantly
alter HIF-1a transcription (Figure 4A) and still induced HIF-1a
protein expression in the presence of the transcription inhibitor
Actinomycin D (Figure 4B) prompted us to check whether lactate
could interfere with the PHD reaction. Considering that PHD
activity requires 2-oxoglutarate as a substrate and may therefore
be influenced by other carboxylates [21–23], we designed
competition experiments between lactate and 2-oxoglutarate in
normoxic ECs. Addition of 2-oxoglutarate to ECs concentration-
dependently reduced the abundance of HIF-1a in ECs exposed to
lactate (Figure 4C; a representative blot is shown in Figure S4A).
We also used an ODD-Luc construct to detect PHD activity [30]
and showed that 10 mM lactate triggered ODD-driven luciferase
activity as efficiently as 150 mM CoCl2 (Figure 4D).
We next aimed to determine whether lactate or pyruvate
(resulting from intracellular lactate oxidation) exerted these effects
on PHD activity. Pyruvate cannot be detected using NMR.
Therefore, we developed an enzymatic assay to show that
exposure of ECs to exogenous lactate led to a time-dependent
increase in intracellular pyruvate (Figure 4E). Lactate oxidation to
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pyruvate is preferentially catalyzed by the lactate dehydrogenase-B
(LDH-B) gene product. We found that the LDH competitor
oxamate [31] actually blocked lactate-induced HIF-1a protein
expression in normoxic ECs, a property which was not shared by
the structurally-related monocarboxylate acetate (Figure 4F, a
representative blot is shown in Figure S4B). Oxamate inhibits both
LDH-A and LDH-B. To confirm the involvement of LDH-B,
LDH-B was silenced with a specific siRNA (see Figure S5A). This
also prevented lactate-induced HIF-1a expression (Figure 4G and
Figure S4C). Finally, we also provided evidence that pyruvate was
a more potent inducer of HIF-1a than lactate in normoxic ECs
(Figure 4H).
Targeting MCT1 blocks lactate-induced HIF-1 activation
in normoxic ECs
The lactate anion can shuttle between extracellular and
intracellular compartments through monocarboxylate transporters
(MCTs) among which MCT subtypes 1–4 function as passive
lactate-proton symporters [32,33]. Using quantitative PCR to
compare mRNA levels of these 4 transporters, we identified MCT1
as the main transcript in HUVECs (Figure 5A). The correspond-
ing protein was localized at the plasma membrane of the cells, as
shown by immunocytochemistry in Figure 5B and in Figure S3B
where MCT1, its anchor protein basigin/CD147 and the
endothelial marker CD31 colocalized. Because MCT1 mediates
the uptake of lactate in several cell types [26,32,33], we checked
whether MCT1 was involved in lactate signaling in ECs. Silencing
MCT1 with a specific siRNA (see Figure S5B for target extinction)
prevented HIF-1a protein stabilization in HUVECs incubated
with lactate (10 mM) for 24 h (Figure 5C). Consistent with the
involvement of MCT1, a-cyano-4-hydroxycinnamate (CHC), a
reversible inhibitor that has a 10-fold selectivity for MCT1
compared to other MCTs [34], prevented lactate-induced HIF-1a
protein expression not only in HUVECs (Figure 5D) but also in
BAECs (Figure 5E) without showing intrinsic EC toxicity (Figure
S6). These results were verified using a series of known MCT1
inhibitors that all successfully blocked lactate-induced HIF-1a
protein stabilization in BAECs (Figure S7). The functional
Figure 1. Endothelial cells import exogenous lactate. (A and B) HUVECs were incubated during 6-h with 10 mM of 13C-methy-labeled sodium
lactate (left panels) or 10 mM of 12C sodium lactate (right panels). 13C-lactate was detected using nuclear magnetic resonance (NMR) in cell lysates.
(A) In 13C NMR spectra, a 13C-Lactate peak is detected at 19 ppm. (B) In 1H NMR spectra, the methyl doublets at 1.56 and 1.30 ppm arise from 13C-
lactate whereas the doublet at 1.43 ppm arises from a coincidental overlap of endogenous 12C-Lactate and threonine. (C) HUVECs were incubated
with 10 mM sodium L-lactate. L-Lactate was detected using an enzymatic assay in the lysate of cells collected at different time points. *p,0.05; n= 4.
Error bars reflect mean 6 SEM.
doi:10.1371/journal.pone.0033418.g001
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consequence of MCT1 inhibition was addressed by measuring
changes in VEGFR2 expression. CHC blocked lactate-induced
upregulation of VEGFR2 protein expression in HUVECs
(Figure 5D) and in BAECs (Figure 5E). It also reduced basal
HIF-1a and VEGFR2 protein expressions in HUVECs
(Figure 5D). We ruled out a major contribution of two known
Figure 2. Lactate activates HIF-1 in normoxic endothelial cells. HUVECs were incubated during 24-h with 10 mM lactate or not. (A) The
transcriptional activity of HIF-1 was determined using a dual luciferase reporter assay in HUVECs. *p= 0.0207; n= 4. (B) VEGF protein level was
measured using ELISA in the supernatant of cells. ns, non-significant; n=6. (C) bFGF protein level was measured using ELISA in the supernatant of
cells. ***p,0.0001; n= 5. (D) VEGFR2 protein expression was detected by western blot in cell lysates. **p= 0.0084; n=4–5. (A–D) Error bars reflect
mean 6 SEM.
doi:10.1371/journal.pone.0033418.g002
Figure 3. Lactate induces an increase in HIF-1a protein expression in normoxic endothelial cells. HIF-1a protein expression was detected
by western blot in normoxic ECs. (A) HUVECs were incubated during 24-h with 10 mM lactate or not. **p= 0.0014; n=8. (B) as in (A) but with BAECs.
***p,0.0001; n=16–17. (C) BAECs were incubated during 24-h with the indicated concentrations of lactate. **p,0.01; n=4. (D) BAECs were
incubated during the indicated times with 10 mM of lactate. *p,0.05; n= 5–12. (A–D) Error bars reflect mean 6 SEM.
doi:10.1371/journal.pone.0033418.g003
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HIF-1 activators, nitric oxide (NO) and reactive oxygen species
(ROS) [30], in our experimental conditions. Lactate-driven HIF-
1a and VEGFR2 protein expressions were indeed resistant to the
NO synthase inhibitor Nv-nitro-L-arginine methyl ester (L-
NAME) and to the general antioxidant N-acetyl-L-cysteine
(NAC) (Figure 5E).
Targeting MCT1 inhibits lactate-induced angiogenesis in
tumors
We next investigated whether lactate-induced HIF-1 activation
conferred an angiogenic phenotype to ECs. We first observed that
lactate increased ECmotility, as illustrated by the increased capacity
of confluent ECs to colonize a cell-free area in the presence of
lactate compared to vehicle (Figure 6A). Lactate-induced migration
was quantified in transwell experiments in which ECs in the upper
chamber had to invade a layer of Matrigel matrix to reach the
bottom well containing lactate. In this assay, 10 mM lactate
promoted EC migration as efficiently as 10 ng/ml VEGF
(Figure 6B). EC migration was partly inhibited by CHC, indicating
that lactate uptake is as an integral part of the migratory phenotype.
The involvement of MCT1 in lactate-induced endothelial invasion
was further tested ex vivo. A 3D-culture of aortic rings in collagen gels
was used to evaluate the outgrowth of linear endothelial structures
from the preexisting vessel [35]. Both basal and lactate-induced
endothelial responses were completely blocked by CHC (Figure 6C).
The inhibition was sustained but reversible, as sprouting eventually
resumed 14 days after the CHC treatment.
The angiogenic conversion of ECs was also assayed on Matrigel
[36]. In this assay, lactate alone promoted sustained endothelial
tube formation (Figure 7A), a response that was completely
inhibited using SU5402 (targeting VEGF and bFGF receptors),
echinomycin (an inhibitor of the transcriptional activity of HIF-1),
Figure 4. Lactate triggers HIF-1 induction in normoxic endothelial cells. Lactate was used at 10 mM for 24-h. (A) HIF-1a mRNA was detected
using qRT-PCR in HUVECs incubated with lactate. ns, non-significant; n= 4. (B and C). HIF-1a protein expression was detected by western blot in
BAECs incubated with lactate and/or (B) 5 mg/ml Actinomycin D (**p,0.01, ***p,0.005, ns, non-significant compared to control, n=3–4); (C)
increasing concentrations of 2-oxoglutarate. *p,0.05, **p,0.01; n= 5–6. (D) ODD-driven luciferase activity was assessed in HUVECs incubated with
150 mM CoCl2 or lactate. **p,0.01; n= 5. (E) Intracellular pyruvate was detected using an enzymatic assay in HUVECs incubated with lactate.
**p,0.01; n= 4. (F–H) HIF-1a protein expression was detected by western blot. (F) BAECs were incubated with lactate, oxamate (10 mM), and/or
acetate (10 mM). **p,0.01, ***p,0.005, ns, non-significant compared to control cells without lactate; n=4–16. (G) HUVECs transfected with the
indicated siRNA were incubated with lactate. *p= 0.0170, **p= 0.0019 compared to control; ##p= 0.0056 compared to lactate alone; n= 3–9. (H)
BAECs were incubated with pyruvate (10 mM), lactate, or not. **p,0.01 compared to control; n= 3–19. (A–H) Error bars reflect mean 6 SEM.
doi:10.1371/journal.pone.0033418.g004
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and the MCT1 inhibitor CHC (Figure 7B). Using undiluted
Matrigel, we demonstrated that MCT1 silencing with a specific
shRNA not only inhibited lactate-induced tubulogenesis but also
basal tubulogenesis (Figure S8), suggesting autocrine lactate
signaling in cultured ECs.
We performed in vivo experiments to validate lactate as a pro-
angiogenic agent and MCT1 as a new anti-angiogenic target.
First, Matrigel plugs were implanted subcutaneously in each flank
of mice, the left plug containing 10 mM lactate and the right plug
an equal volume of saline. Seven days later, CD31 immunolabel-
ing of collected plugs revealed a ,10-fold increase in the
endothelial colonization of lactate-containing plugs compared to
controls (Figure 8A). Most vascular structures adopted a circular
shape and were perfused (Figure 8A, inset), thus confirming lactate
Figure 5. Targeting MCT1 inhibits lactate-induced HIF-1 activation in normoxic endothelial cells. (A) Relative mRNA expression was
determined in confluent HUVECs using quantitative RT-PCR. n=3. Error bars reflect mean 6 SEM. (B) Immunostaining showing the membrane
expression of MCT1 in HUVECs (upper panel) and negative control (lower panel, omission of primary antibody). Bar = 40 mm. (C) HUVECs transfected
with the indicated siRNA were incubated during 24-h with 10 mM lactate or not. HIF-1a protein expression was detected by western blot. *p,0.05,
***p,0.005 compared to control; ###p,0.005 compared lactate alone; n= 6–14. (D and E) HIF-1a and VEGFR2 protein expression was detected by
western blot. (D) HUVECs were incubated during 24-h with 10 mM lactate and/or 5 mM a-cyano-4-hydroxycinnamate (CHC). *p,0.05, **p,0.01,
***p,0.005 compared to control; ###p,0.005 compared to lactate alone; n=3–12. (E) BAECs were incubated during 24-h with 10 mM lactate, 5 mM
Nv-nitro-L-arginine methyl ester (L-NAME), 5 mM a-cyano-4-hydroxycinnamate (CHC), and/or 5 mM N-acetyl-L-cysteine (NAC). *p,0.01, ***p,0.005
compared to control; ###p,0.005 compared to lactate alone; n=3–14. (C–E) Error bars reflect mean 6 SEM.
doi:10.1371/journal.pone.0033418.g005
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as a pro-angiogenic agent. In a second set of experiments, we
tested the anti-angiogenic activity of CHC in tumors. Comparison
of size-matched mouse Lewis Lung carcinoma (LLc) tumors
showed that chronic MCT1 inhibition reduced the endothelial
density at vascular hotspots by ,2-fold compared to vehicle
treatment (Figure 8B). In this model, CHC may interfere with the
metabolic activity of MCT1-expressing tumor cells [26]. To better
discriminate between direct and indirect anti-angiogenic effects,
we repeated the experiment using MCT1-negative hepatocarci-
noma (TLT) cells that were previously shown to be insensitive to
the metabolic regulation by CHC [26]. Intravital microscopy
revealed that chronic MCT1 inhibition completely prevented
tumor angiogenesis in this model (Figure 8C). While new vascular
structures continuously developed during the growth of saline-
treated tumors, the angiogenic phenotype was lost in response to
CHC administration (see pictures at day +12). Hemorrhagic foci
were already observed after 8-days of treatment.
Discussion
The two main findings of our study are (i) that lactate stimulates
HIF-1 activity directly in normoxic ECs resulting in the increased
expression of relevant pro-angiogenic targets including the
prototypical VEGF receptor VEGFR2, and (ii) that the anti-
angiogenic effects of MCT1 inhibition include inhibition of HIF-1
activation in ECs. This activity was initially identified in vitro using
two different EC lines in which MCT1 was targeted pharmaco-
logically or using RNA interference. It was confirmed in vivo by
using the experimental MCT1 inhibitor CHC in two different
tumor types.
Our demonstration is based on the unprecedented identification
in ECs of a lactate-signaling pathway leading to HIF-1 activation
under normoxia. This pathway involves lactate uptake, the
conversion of lactate to pyruvate by LDH-B, a competition
between pyruvate and 2-oxoglutarate supporting a pyruvate-
mediated inhibition of PHD2, and, consequently, HIF-1 activation
independently of hypoxia (Figure 9). Lactate did not increase the
oxygen consumption rate of ECs (see Figure S1B), ruling out a
contribution of metabolic hypoxia to HIF-1 activation. A similar
effect of monocarboxylates including pyruvate and lactate has
been previously described in malignant cells by Lu et al. [21,22].
Final effectors are however different. While lactate was shown to
promote VEGF production by tumor cells [22], we show here that
in ECs, it upregulates VEGFR2 expression without modulating
Figure 6. Targeting MCT1 inhibits lactate-induced endothelial cell migration and vascular sprouting. (A) Confluent BAECs on coverslips
were placed into cell-free dishes in the presence of 10 mM lactate or not. Pictures show cell migration over time. Bar = 50 mm. (B) Quantification of EC
migration was performed in a transwell assay in which calcein-labeled BAECs migrated during 24-h through a Matrigel-coated membrane towards
serum-free medium containing 10 ng/ml VEGF, 10 mM lactate, or lactate and 5 mM CHC. Pictures show the membranes where pores occupied by
endothelial cells (detected using a caveolin-1 antibody) are labeled with a red bullet. Bar = 50 mm. The graph shows calcein fluorescence in the
bottom well. **p,0.01, ***p,0.005 compared to control; ###p,0.005 compared to lactate; n=3. (C) Consecutive rings of a mouse aorta were
cultured during 10 days in collagen gels containing 10 mM lactate and/or 2 mM CHC. Pictures show endothelial sproutings (arrowhead point at
typical linear structures) and fibroblast seeding (scattered cells). Bar = 500 mm. The graph shows the number of sprouts per ring. ***p,0.005
compared to control; ###p,0.005 compared to lactate; n=6–11. (B and C) Error bars reflect mean 6 SEM.
doi:10.1371/journal.pone.0033418.g006
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VEGF protein secretion despite increased VEGF-A gene transcrip-
tion. Because VEGFR2 is the main transducer of the pro-
angiogenic effects of VEGF [27], one can logically propose that, in
complex tumor tissues, lactate exquisitely stimulates VEGF
signaling by acting on both the growth factor and its cognate
receptor. This paradigm is further supported by the influence of
lactate on stromal cells. Lactate indeed promotes VEGF
production by fibroblasts and macrophages [18,19], and enhances
VEGF activity through inhibition of ADP-ribosylation in several
cell types [18–20]. Of note, the existence of a HIF-1a-driven,
VEGF-mediated autocrine loop in ECs could further reinforce the
anti-angiogenic effects of MCT1 inhibition in ECs [37,38].
Finally, it should be emphasized that although the lactate
induction of the VEGF/VEGFR2 signaling pathway is indepen-
dent of hypoxia in the target cells, lactate may arise from
anaerobic glycolysis [24] as well as aerobic glycolysis (the Warburg
effect) [39], or through the malate shuttle from the oxidative
metabolism of glucose and glutamine [40,41]. Lactate flux rate is
likely to be different between ‘‘target’’ cells signaling through
lactate vs cells consuming or producing lactate. For instance, while
lactate-fueled respiration of tumor cells requires high-rate lactate
uptake and high MCT1 expression [26], lower MCT1 expression
in ECs could efficiently support the low-rate lactate uptake
accounting for lactate signaling. Different levels of MCT1
expression could explain why Koukourakis et al. [42] failed to
detect MCT1 in the vascular structures of colorectal adenocarci-
nomas using immunohistochemistry.
Although we focused on the paradigm that HIF-1a-driven
VEGFR2 receptor expression is a target of MCT1 inhibition to
account for the observed anti-angiogenic effects, inhibition of other
pro-angiogenic HIF-1a targets is very likely to support the
functional impact of blocking lactate transport in ECs. For instance,
we found that bFGF release was increased in response to lactate
(Figure 2C) and thus that in the absence of increased VEGF, the
inhibition of lactate-induced tubulogenesis on Matrigel with
SU4502, a mixed inhibitor of VEGFR2 and fibroblast growth
factor receptor 1 (FGFR1) (Figure 7B), strongly suggests that bFGF
participates to the pro-angiogenic effects of lactate. Of interest is also
the ability of bFGF to stimulate the activity of aminophospholipid
translocase in ECs [43], an enzyme required for the maintenance of
lipid asymmetry of the membrane, proper membrane anchorage of
proteins, endocytosis and membrane recycling [44,45]. In erythro-
cytes, GLUT-dependent arabinose transport and MCT-dependent
lactate transport were shown to be inhibited by cleavage of either
phosphatidylcholine or sphingomyelin [46], stressing out that
membrane fluidity and asymmetry are important for the activity
of these transporters. Whether lactate-induced bFGF production
facilitates the membrane translocation of transporters (such as
MCT1) and receptors (such as bFGFR and VEGFR2) involved in
the angiogenic phenotype of ECs warrants further investigation.
More generally, previous work indicates that targeting MCT1
offers the possibility to simultaneously inhibit several major pro-
angiogenic pathways with a single therapeutic molecule. First,
MCT1 inhibition may interfere with the viability of angiogenic-
factor-producing-cells including cancer cells, macrophages and
fibroblasts; all these cells express MCT1 [26,42]. Note that the
impact may be indirect since MCT1 inhibition in oxidative tumor
cells may favor the death of hypoxic glycolytic cells [26], and
alteration in the fibroblast capacity to take up lactate and export
pyruvate (both through MCT1) in tumors may reduce tumor cell
Figure 7. MCT1 inhibition blocks lactate-induced endothelial tube formation. HUVECs were seeded on growth factor-reduced Matrigel
containing 10 mM lactate or not and monitored for their ability to generate vascular tubes. (A) Pictures of the upper panel show endothelial network
formation over time (bar= 500 mm), which was quantified in the lower graph. n=4. Error bars reflectmean6 SEM and are sometimes smaller than symbols.
(B) The tube formation assay was performed in the presence of 10 mM SU5402 (targeting VEGF and bFGF receptors), 10 nM echinomycin (targeting the
transcriptional activity of HIF-1), or 2 mM of CHC (targeting MCT1). Pictures were captured after 8-h of culture in the Matrigel matrix. Bar = 200 mm.
doi:10.1371/journal.pone.0033418.g007
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proliferation [42]. Second, as documented in a previous study,
MCT1 inhibition can block lactate-induced NF-kB activation in
ECs, with a subsequent downregulation of autocrine IL-8 signaling
and IL-8-mediated angiogenesis [23]. Interestingly, this latter
effect was also in part dependent on a direct competition between
2-oxoglutarate and lactate for PHD2. Given this mode of action,
other targets may be anticipated. For example, 2-oxoglutarate is a
necessary cofactor for factor inhibiting HIF-1 (FIH-1), a 2-
oxoglutarate-dependent dioxygenase that inactivates HIF-1
through HIF-1a asparagine hydroxylation [47]. Because PHDs
and FIH-1 are simultaneously inhibited by compounds such as
dimethyloxalylglycine that displace 2-oxoglutarate from the active
enzyme sites [48], our data suggest that lactate-dependent
dioxygenase inhibition may extend to FIH-1. Both PHD2 and
FIH-1 also control HIF-2 activity through regulating HIF-2a
hydroxylations [49], suggesting that the activity of lactate could
further include HIF-2 activation in ECs. HIF-1 and HIF-2 control
both different and overlapping sets of genes modulating angio-
genesis and vascular stability and maturation, respectively [50–
53]. Whether the detection of mature blood vessels in lactate-
Figure 8. MCT1 inhibition blocks tumor angiogenesis. (A) Two Matrigel plugs were implanted subcutaneously in the same mouse, one
containing 10 mM lactate (left flank) and the other one an equal volume of saline (right flank). Plugs were microdissected 7 days after implantation.
Pictures show CD31 immunostainings (bar = 100 mm; inset: a vascular structure carrying red blood cells), which were quantified in the graph.
***p= 0.0007; n= 4. Error bars reflect mean 6 SEM. (B and C) On Day 0, mice were randomly assigned to treatment groups consisting of daily i.p.
injections of CHC (1 mmol/Kg) or vehicle. (B) Mice carrying LLc tumors (461 mm) were treated. Pictures show CD31 immunostainings of size-
matched tumors (bar = 20 mm), which were quantified in the graph. **p=0.0051; n=4. Error bars reflect mean 6 SEM. (C) Intravital microscopy
pictures were captured over time in treated mice carrying tumors generated with MCT1-negative TLT tumor cells. Bar = 1 mm.
doi:10.1371/journal.pone.0033418.g008
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containing Matrigel plugs (Figure 8A) and the apparent anti-
vascular effects of MCT1 inhibition in vivo (Figure 8C) are related
to changes in endothelial HIF-2 activity remains to be determined.
The anti-angiogenic effects of MCT1 inhibitors that we document
here offers an additional rationale for the antitumor effects of
MCT1 inhibitors that we identified previously in several types of
tumors and attributed to metabolic effects [26]. In a model of
colon cancer xenograft involving the co-injection of HUVECs, a
downregulation of MCT1 expression in ECs was indeed
documented to significantly retard tumor growth [23].
In conclusion, we have shown that lactate activates HIF-1 in
normoxic ECs and consecutively promotes the expression of bFGF
and VEGFR2, the latter reinforcing the stimulation of the VEGF
signaling pathway promoted by the lactate-induced VEGF expression
occurring in tumor and stromal cells. Importantly, we also report that
in ECs, MCT1 inhibition can thus drive direct anti-angiogenic effects
through a reduction in HIF-1 activity, which, together with the
antimetabolic effects of MCT1 inhibition on tumor cells, considerably
enlarges the therapeutic potential of this class of drugs.
Materials and Methods
Cells and chemicals
BAECs (Clonetics) were routinely cultured in EBM-EGM
(Cambrex), HUVECs (Clonetics) in EBM2-MV (Cambrex), and
LLc (LGC Standards, [54]) and TLT (originally obtained at from HS
Taper, University of Louvain [55]) tumor cells in DMEM containing
4500 mg/liter glucose (Invitrogen) with 10% FBS at 5% CO2 and
21% O2, 37uC. Glucose-deprived DMEM was from Krackeler
Scientific. Media were supplemented with 1% penicillin-streptomy-
cin. All experiments were performed in pyruvate-free media buffered
at pH 7.3 (3.7 g/liter NaHCO3). To minimize fluctuations due to
unequal growth rates, all assays were performed on confluent cells.
Hypoxia (1% O2) was achieved as previously described [56]. Cell
death was quantified using the NucleoCounter device from
ChemoMetec. Unless stated otherwise, all chemicals including
CHC were from Sigma. Carboxylates were used as sodium salts.
Determination of intracellular L-lactate and pyruvate
For NMR experiments, HUVECs in EBM2 media were
incubated during 6-h to 10 mM 13C-methyl-labeled lactate (Isotec,
Sigma), washed twice with DPBS, lysed and collected in 0.9 M
perchloric acid (1:10 in diH2O).
12C-(unlabeled)-lactate was used as
control. Lysates were spun at 4uC for 10 min at 12,000 rpm. 13C
and 1H NMR spectra acquisitions were performed on supernatants
using a 500-MHz Varian Inova spectrometer equipped with a 5-
mm tunable broadband probe. 13C-NMR spectra were acquired at
125.7 MHz with 45u flip angle, 0.8-second interpulse delay, a
1.334 s acquisition time, and at a temperature of 25uC. Control
runs of known concentrations of lactate were used to assess peak
Figure 9. Model illustrating the anti-angiogenic activity of MCT1 inhibitors targeting lactate-induced HIF-1 activation in
endothelial cells. HIF-1 activity primarily depends on the stability of HIF-1a. When HIF prolylhydroxylase (PHD) is active as it is the case for normoxic
endothelial cells (ECs) in oxidative tissues (left), HIF-1a is hydroxylated and addressed to the proteasome for degradation. PHD requires 2-oxoglutarate
as a substrate and is competitively inhibited by pyruvate. Normoxic ECs in glycolytic tissues such as tumors (right) take up exogenous lactate
originating from distant hypoxic cells, a process under the control of monocarboxylate transporter 1 (MCT1). ECs do not primarily use lactate as a fuel
for oxidative phosphorylation (OXPHOS). Lactate oxidation by LDH-B rather increases the pool of intracellular pyruvate, now available to compete
with 2-oxoglutarate from PHD, resulting in HIF-1a protein stabilization, HIF-1 activation, and angiogenesis. Because MCT1 is the main transporter for
lactate uptake by ECs, targeting MCT1 inhibits lactate-induced angiogenesis in tumors. Abbreviations: asc., ascorbate; dehydroasc.,
dehydroascorbate; GLUT, glucose transporter.
doi:10.1371/journal.pone.0033418.g009
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shape and ppm position. VNMRJ software by Varian (Cary, NC)
was used to acquire and analyze spectra. All samples were tuned
and shimmed before data acquisition. For enzymatic measure-
ments, confluent HUVECs were incubated with 10 mM L-lactate,
washed twice with PBS containing 10 mM D-Lactate (to saturate
MCTs), and lysed in 200 ml ice-cold RIPA Buffer (50 mM Tris
HCL pH 7.4, 150 mM NaCl, 1% Triton-x 100, 0.05% sodium
deoxycolate, 0.1% SDS,1 mM EDTA, 1 mM Na3VO4 and
protease inhibitors). Samples were filtered through centrifugation
columns with a 10 KDa cutoff. L-Lactate and pyruvate concentra-
tions were quantified in clear cell lysates using specific enzymatic
assays on an ISCUSflex analyzer (CMA Microdialysis AB).
Oximetry
Determination of cell oxygen consumption rates was carried out
using electron paramagnetic resonance (EPR) in DMEM contain-
ing 4500 mg/liter glucose, dextran 10% [57]. Briefly, 26107
viable cells/ml were sealed in glass capillary tubes in the presence
of 0.08 mM of the O2 sensor 4-oxo-2,2,6,6-tetramethylpiperidine-
d-15N-1-oxyl (CDN isotopes) and with 10 mM lactate where
indicated. Cells were maintained at 37uC during recording on a
Bruker EMX EPR spectrometer operating at 9 GHz.
Dual luciferase reporter assays
Dual luciferase reporter assays were performed with the dual
luciferase kit (DLR) from Promega using pGL3-(PGK-HRE6)-
TK-Luc as reporter of HIF-1 activity [10] and pODD-Luc as
reporter of PHD activity [30]. Cells were transfected using
electroporation (Amaxa Nucleofector, Lonza).
Western blotting, immunohistochemistry and antibodies
We used previously disclosed protocols for immunocytochemistry
and immunohistochemistry [58] except that HUVECs were
permeabilized with 0.05% saponin for MCT1 detection. Western
blotting (WB) was done as previously shown [59] with the slight
modification that proteins were not heat-denaturated for HIF-1a
protein detection. This allowed the detection, in whole cell lysates, of
basal HIF-1a that would otherwise not be detected [60]. For Figure
S2, nuclear extraction was performed according to manufacturer’s
recommendations using the nuclear extraction kit fromActive Motif.
Primary antibodies were: a mouse monoclonal against HIF-1a (BD),
a rabbit polyclonal raised against an intracellular epitope of MCT1
(AB3538P, Chemicon), a rabbit polyclonal against caveolin-1 (BD), a
rabbit polyclonal against laminin A/C (Santa Cruz), a goat
polyclonal raised against an epitope comprising an an extracellular
domain of VEGFR2 (R&D) for immunohistochemistry, a mouse
monoclonal against VEGFR2 (Santa Cruz) for WB, a mouse
monoclonal against CD147 (BD), a mouse monoclonal against b-
actin (Sigma), a mouse monoclonal against CD31 (Dako) for Figure
S3, and a rat monoclonal against CD31 (BD) for Figure 8. For
immunohistochemistry, areas of positive staining were quantified
using the Framework for Image Dataset Analysis (FRIDA) software
developed by Johns Hopkins University.
ELISA
VEGF-A and bFGF protein levels were measured in the
supernatant of confluent HUVECs using the Human VEGF
Quantikine ELISA Kit (R&D) and the Human bFGF Quantikine
ELISA kit (R&D) according to manufacturer’s instructions.
PCR and RNA interference
The effects of a 24-h exposure of HUVECs to lactate and saline
were compared using the Human Angiogenesis RT2 Profiler PCR
Array from SABiosciences, according to manufacturer’s instruc-
tions. In each condition, total mRNA extracted from 3 independent
dishes was pooled. To silence MCT1 and LDH-B mRNAs,
HUVECs were transfected with specific siRNAs as reported
previously [61]. siRNAs (Qiagen) targeted the following sequences:
hMCT1 AAGAGGCUGACUUUUCCAAAU, hLDHB AAGA-
UUGUAGUGGUAACUGCA. Allstar siRNA (Qiagen) was used
as negative control. MCT1 shRNA was purchased from Open
Biosystems (clone TRCN0000038340); scrambled control shRNA
was Addgene plasmid 1864. The following primers were used for
SYBR green quantitative PCR [61]: hMCT1 sense, 59-GTGG-
CTCAGCTCCGTATTGT-39, antisense, 59-GAGCCGACCTA-
AAAGTGGTG-39; hMCT2 sense, 59-CAACACCATTCCAAG-
ACAGC-39, antisense 59-TGGCTGTTATGTACGCAGGA-39;
hMCT3 sense, 59- GGATGTGTT-GAAGAACTATGAGATC-
39, antisense 59-CCGGGTTCCTCTGCAACA-39; hMCT4 sense,
59-CAGTTCGAGGTGCTCATGG-39, antisense, 59- ATGTA-
GACGTGGGTCGCAT-39. Housekeeping human ribosomal pro-
tein L19 (hRPL19) primers were sense, 59-CAAGCGGATTCT-
CATGGAACA-39, antisense, 59-TGGTCAGCCAGGAGCTT-
CTT-39.
Endothelial cell migration assays
To image EC migration, we used an assay analogous to a scratch
injury test [62]. BAECs were cultured to confluence on gelatin-
coated circular coverslips, which were then transferred to adhere
onto 100 mm gelatin-coated dishes containing EBM-EGM without
serum and growth factors, and supplemented with lactate (10 mM)
or not. Images of migrating cells were captured at the migration
front around the coverslip margin. For quantification, BAECs were
prestained with calcein and 50,000 cells were seeded in the upper
chamber of the Matrigel-coated insert plate of a Biocoat Tumor
Invasion System (BD). Bottom wells contained EGM-MV without
serum and growth factors, supplemented with lactate (10 mM),
VEGF (10 ng/ml, Sanvertech), CHC (5 mM) and/or saline.
Twenty-four hours later, cells on the underside of the Fluoroblock
membranes were quantified by measuring fluorescence at 535 nm
after an excitation at 485 nm. Detached membranes were also fixed
in 4% paraformaldehyde for 10 minutes and processed for
immunohistochemistry using anti-caveolin-1 antibodies.
Endothelial tube formation and aortic ring angiogenesis
assays
Capillary-like tube formation [63] and mouse aorta ring assays
[35] were performed as previously described. Where indicated,
inhibitors were present both in the gels and in the supernatants.
In vivo experiments
All mice were from Elevage Janvier. Where indicated, vehicle or
CHC (25 mmol in 200 ml, [64]) was daily injected i.p. We used
RJ:NMRI mice and an existing protocol for Matrigel plug
implantation [58]. The protocols used for intramuscular tumor
growth and intravital microscopy have also been reported
previously [65,66]. LLc cells were injected into syngeneic male
6–8 week-old C57/Bl6 J mice and TLT cells into syngeneic male
RJ:NMRI mice. Surgery and imaging were performed on
anesthetized (ketamine/xylazine) animals. All in vivo experiments
were performed with approval of Duke University Institutional
Animal Care and Use Committee (specific approval ID for this
study was A069-03-02) and by Universite´ catholique de Louvain (UCL)
authorities (Comite´ d’Ethique Facultaire pour l’Experimentation Animale,
specific approval ID for this study was TUMETABO) according to
national animal care regulations.
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Statistical analyses
Results are expressed as mean 6 SEM. Student’s t test and 1-
way ANOVA (Tukey’s post-hoc test) were used where convenient.
p,0.05 was considered statistically significant.
Supporting Information
Figure S1 Lactate does not support EC survival through
increased oxygen consumption and CHC is devoid of
intrinsic toxicity. (A) HUVEC death was determined with a
NucleoCounter. Confluent cells were assayed after 4-h of culture
in serum-free DMEM containing the indicated substrates.
*p,0.05 compared to glucose; n=3. (B) EPR oximetry was used
to determine the rate of oxygen consumption by HUVECs in
DMEM containing 4500 mg/L glucose 610 mM lactate. Slopes
calculated from linear regressions are not statistically different
(21.97360.174 for glucose, 21.90260.275 for glucose+lactate,
p=0.84, n=3). (A and B) Error bars reflect mean 6 SEM.
(PDF)
Figure S2 Lactate induces the nuclear translocation of
HIF-1a in HUVECs. HIF-1a protein expression was detected by
Western blot in the cytosol (laminin A/C-negative fraction, 8 mg of
total protein per well) and nucleus (laminin A/C-positive fraction,
10 mg of total protein per well) of HUVECs after a 24-h treatment
with hypoxia or lactate as indicated. Densitometric analyses of HIF-1a
protein expression (% of control) are provided below the correspond-
ing bands; the experiment was repeated twice with similar results.
(PDF)
Figure S3 Membrane expression of VEGFR2 and MCT1
in ECs. (A) HUVECs were treated during 24 h with 10 mM lactate
or not, after which the cells were immunostained with an antibody
raised against an epitope comprising an extracellular domain of
VEGFR2. Nuclei were stained with DAPI. Shown are representative
pictures indicating that lactate stimulates the membrane expression
of VEGFR2 in normoxic ECs. Omission of primary antibodies was
used for control. (bar= 20 mm). (B) HUVECs were immunostained
using antibodies against MCT1, its chaperon protein CD147, and
CD31, and nuclei were stained with DAPI. Shown are representa-
tive pictures, including a merged picture, indicating that all 3
proteins colocalize at the cell membrane. Omission of primary
antibodies was used for control. (bar= 20 mm).
(PDF)
Figure S4 Inhibition of lactate-induced HIF-1a expres-
sion by 2-oxoglutarate, oxamate and LDH-B silencing.
Representative western blots are shown. (A and B) HIF-1a and b-
actin protein expressions were detected in BAECs treated during
24-h as indicated with (A) 10 mM lactate and increasing
concentrations of the PDH substrate 2-oxoglutarate (2-OG), (B)
10 mM lactate and/or 10 mM oxamate. (C) HUVECs were
transfected with a specific siRNA against LDH-B or with a
scrambled siRNA, and treated during 24-h with 20 mM lactate
where indicated. The representative western blot shows HIF-1a,
LDH-B and b-actin protein expressions.
(PDF)
Figure S5 Protein extinctions in HUVECs after siRNA/
shRNA delivery. Representative western blots and quantifica-
tion graphs are shown for HUVECs transfected with (A) a specific
siRNA against LDH-B or a control siRNA (n=2), or (B) a specific
shRNA against MCT1 or a control shRNA. n=3. (A and B) Error
bars reflect mean 6 SEM.
(PDF)
Figure S6 CHC is devoid of intrinsic toxicity for ECs.
HUVEC death was determined with a NucleoCounter. Confluent
cells were assayed after 24-h culture in EBM2-MV containing
glucose and serum and supplemented with lactate or CHC as
indicated. ns, non-significant; n=4. Error bars reflect mean6 SEM.
(PDF)
Figure S7 VariousMCT1 inhibitors block lactate-induced
HIF-1a protein expression in normoxic ECs. BAECs were
treated during 24-h with 10 mM lactate and the MCT1 inhibitors
indicated. *p,0.05, **p,0.01 compared to control; ##p,0.01,
###p,0.005 compared to lactate alone; n=4. Error bars reflect
mean 6 SEM. NPPB, 5-nitro-2-[3-phenylpropylamino]-benzoate.
(PDF)
Figure S8 MCT1 modulates basal and lactate-induced
angiogenesis. HUVECs transfected with a shRNA against
MCT1 (target extinction= 86.763.3%) or with a scrambled (Scr)
shRNA were seeded on undiluted growth factor-reduced Matrigel
containing 10 mM lactate or not and monitored for their ability to
generate vascular tubes. Shown are representative pictures (n=3)
captured after 12-h of culture. Bar = 1 mm.
(PDF)
Table S1 Genes activated by lactate in normoxic ECs
(RT2 Profiler PCR Array).
(PDF)
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